Sarepta Therapeutics Inc (SRPT) - Net Assets
Based on the latest financial reports, Sarepta Therapeutics Inc (SRPT) has net assets worth $1.32 Billion USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.49 Billion) and total liabilities ($2.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SRPT asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.32 Billion |
| % of Total Assets | 37.79% |
| Annual Growth Rate | 25.72% |
| 5-Year Change | 100.55% |
| 10-Year Change | 702.61% |
| Growth Volatility | 409.38 |
Sarepta Therapeutics Inc - Net Assets Trend (1995–2024)
This chart illustrates how Sarepta Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Sarepta Therapeutics Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Sarepta Therapeutics Inc (1995–2024)
The table below shows the annual net assets of Sarepta Therapeutics Inc from 1995 to 2024. For live valuation and market cap data, see market cap of Sarepta Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.53 Billion | +77.78% |
| 2023-12-31 | $859.34 Million | +123.23% |
| 2022-12-31 | $384.95 Million | -58.52% |
| 2021-12-31 | $928.01 Million | +21.82% |
| 2020-12-31 | $761.76 Million | -6.90% |
| 2019-12-31 | $818.19 Million | -20.74% |
| 2018-12-31 | $1.03 Billion | +30.80% |
| 2017-12-31 | $789.22 Million | +134.40% |
| 2016-12-31 | $336.69 Million | +76.88% |
| 2015-12-31 | $190.35 Million | -23.14% |
| 2014-12-31 | $247.65 Million | +0.19% |
| 2013-12-31 | $247.19 Million | +99.87% |
| 2012-12-31 | $123.68 Million | +298.75% |
| 2011-12-31 | $31.02 Million | +1201.06% |
| 2010-12-31 | $-2.82 Million | -111.92% |
| 2009-12-31 | $23.63 Million | +50.20% |
| 2008-12-31 | $15.73 Million | -40.37% |
| 2007-12-31 | $26.38 Million | -30.04% |
| 2006-12-31 | $37.71 Million | -29.72% |
| 2005-12-31 | $53.66 Million | +104.27% |
| 2004-12-31 | $26.27 Million | -39.46% |
| 2003-12-31 | $43.39 Million | +84.80% |
| 2002-12-31 | $23.48 Million | -23.10% |
| 2001-12-31 | $30.53 Million | -8.49% |
| 2000-12-31 | $33.37 Million | +180.38% |
| 1999-12-31 | $11.90 Million | +32.22% |
| 1998-12-31 | $9.00 Million | -50.82% |
| 1997-12-31 | $18.30 Million | +2187.50% |
| 1996-12-31 | $800.00K | -60.00% |
| 1995-12-31 | $2.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sarepta Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 420067400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.00% |
| Other Comprehensive Income | $-218.00K | -0.01% |
| Other Components | $5.74 Billion | 375.65% |
| Total Equity | $1.53 Billion | 100.00% |
Sarepta Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Sarepta Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
North Electro-Optic Co Ltd
SHG:600184
|
$1.86 Billion |
|
National Vision Holdings Inc
NASDAQ:EYE
|
$1.87 Billion |
|
Shenzhen Ysstech Info-Tech Co Ltd
SHE:300377
|
$1.87 Billion |
|
Marriot Vacations Worldwide
NYSE:VAC
|
$1.87 Billion |
|
Ningbo Yongxin Optics Co Ltd
SHG:603297
|
$1.86 Billion |
|
Zhejiang Jingxin Pharmaceutical Co Ltd
SHE:002020
|
$1.86 Billion |
|
Fsilon Furnishing and Construction Materials Corp
SHG:605318
|
$1.86 Billion |
|
Mesoblast Limited
F:LWB
|
$1.86 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sarepta Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 859,337,000 to 1,527,742,000, a change of 668,405,000 (77.8%).
- Net income of 235,239,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 1,136,000.
- Other factors increased equity by 434,302,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $235.24 Million | +15.4% |
| Other Comprehensive Income | $-1.14 Million | -0.07% |
| Other Changes | $434.30 Million | +28.43% |
| Total Change | $- | 77.78% |
Book Value vs Market Value Analysis
This analysis compares Sarepta Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.52x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 12.28x to 1.52x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $1.75 | $21.49 | x |
| 1996-12-31 | $0.57 | $21.49 | x |
| 1997-12-31 | $10.89 | $21.49 | x |
| 1998-12-31 | $4.58 | $21.49 | x |
| 1999-12-31 | $5.31 | $21.49 | x |
| 2000-12-31 | $10.69 | $21.49 | x |
| 2001-12-31 | $8.18 | $21.49 | x |
| 2002-12-31 | $5.48 | $21.49 | x |
| 2003-12-31 | $8.73 | $21.49 | x |
| 2004-12-31 | $4.38 | $21.49 | x |
| 2005-12-31 | $7.21 | $21.49 | x |
| 2006-12-31 | $4.30 | $21.49 | x |
| 2007-12-31 | $2.93 | $21.49 | x |
| 2008-12-31 | $1.36 | $21.49 | x |
| 2009-12-31 | $1.52 | $21.49 | x |
| 2010-12-31 | $-0.15 | $21.49 | x |
| 2011-12-31 | $1.44 | $21.49 | x |
| 2012-12-31 | $5.24 | $21.49 | x |
| 2013-12-31 | $7.30 | $21.49 | x |
| 2014-12-31 | $6.19 | $21.49 | x |
| 2015-12-31 | $4.50 | $21.49 | x |
| 2016-12-31 | $6.91 | $21.49 | x |
| 2017-12-31 | $13.42 | $21.49 | x |
| 2018-12-31 | $15.58 | $21.49 | x |
| 2019-12-31 | $11.11 | $21.49 | x |
| 2020-12-31 | $9.77 | $21.49 | x |
| 2021-12-31 | $11.42 | $21.49 | x |
| 2022-12-31 | $4.40 | $21.49 | x |
| 2023-12-31 | $9.30 | $21.49 | x |
| 2024-12-31 | $14.16 | $21.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sarepta Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.40%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.37%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 2.59x
- Recent ROE (15.40%) is above the historical average (-83.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | -123.81% | -2600.00% | 0.04x | 1.10x | $-2.81 Million |
| 1996 | -262.50% | -2100.00% | 0.02x | 5.25x | $-2.18 Million |
| 1997 | -19.67% | -3600.00% | 0.01x | 1.03x | $-5.43 Million |
| 1998 | -296.67% | -13350.00% | 0.02x | 1.13x | $-27.60 Million |
| 1999 | -69.75% | -8300.00% | 0.01x | 1.08x | $-9.49 Million |
| 2000 | -27.69% | -712.22% | 0.04x | 1.05x | $-12.58 Million |
| 2001 | -88.18% | -3813.21% | 0.02x | 1.11x | $-29.98 Million |
| 2002 | -125.03% | -3508.56% | 0.03x | 1.22x | $-31.71 Million |
| 2003 | -33.68% | -1507.08% | 0.02x | 1.09x | $-18.96 Million |
| 2004 | -94.32% | -5756.08% | 0.02x | 1.09x | $-27.40 Million |
| 2005 | -31.08% | -348.59% | 0.08x | 1.05x | $-22.04 Million |
| 2006 | -82.40% | -26951.81% | 0.00x | 1.08x | $-34.84 Million |
| 2007 | -102.98% | -247.31% | 0.28x | 1.46x | $-29.81 Million |
| 2008 | -152.26% | -112.67% | 0.83x | 1.62x | $-25.53 Million |
| 2009 | -106.47% | -143.07% | 0.29x | 2.54x | $-27.52 Million |
| 2010 | 0.00% | -109.37% | 0.64x | 0.00x | $-31.90 Million |
| 2011 | -7.47% | -4.93% | 0.86x | 1.75x | $-5.42 Million |
| 2012 | -98.07% | -324.91% | 0.18x | 1.66x | $-133.65 Million |
| 2013 | -45.30% | -787.57% | 0.05x | 1.18x | $-136.70 Million |
| 2014 | -54.83% | -1391.71% | 0.03x | 1.19x | $-160.55 Million |
| 2015 | -115.59% | -17560.26% | 0.00x | 1.44x | $-239.06 Million |
| 2016 | -79.38% | -4930.18% | 0.01x | 1.26x | $-300.93 Million |
| 2017 | -6.42% | -32.79% | 0.12x | 1.66x | $-129.61 Million |
| 2018 | -35.06% | -120.22% | 0.18x | 1.59x | $-465.15 Million |
| 2019 | -87.40% | -187.77% | 0.21x | 2.23x | $-796.89 Million |
| 2020 | -72.74% | -102.60% | 0.18x | 3.92x | $-630.30 Million |
| 2021 | -45.13% | -59.66% | 0.22x | 3.39x | $-511.58 Million |
| 2022 | -182.75% | -75.40% | 0.30x | 8.13x | $-741.98 Million |
| 2023 | -62.37% | -43.11% | 0.38x | 3.80x | $-621.91 Million |
| 2024 | 15.40% | 12.37% | 0.48x | 2.59x | $82.46 Million |
Industry Comparison
This section compares Sarepta Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sarepta Therapeutics Inc (SRPT) | $1.32 Billion | -123.81% | 1.65x | $1.86 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exo… Read more